BiotechTube

Apatinib Mesylate, doxorubicin, ifosfamide

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Soft Tissue Sarcoma

Conditions

Soft Tissue Sarcoma

Trial Timeline

Aug 20, 2019 → Dec 31, 2023

NCT ID
NCT04012827

About Apatinib Mesylate, doxorubicin, ifosfamide

Apatinib Mesylate, doxorubicin, ifosfamide is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Soft Tissue Sarcoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT04012827. Target conditions include Soft Tissue Sarcoma.

What happened to similar drugs?

2 of 15 similar drugs in Soft Tissue Sarcoma were approved

Approved (2) Terminated (3) Active (11)
✅daptomycin (up to 14 days)MerckApproved
✅linezolid + vancomycinPfizerApproved
🔄Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
🔄Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
❌Etoricoxib 60 mg + Etoricoxib 90 mgMerckPhase 3
🔄ridaforolimus + PlaceboMerckPhase 3
🔄Diclofenac sodiumNovartisPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04012827Phase 2UNKNOWN

Competing Products

20 competing products in Soft Tissue Sarcoma

See all competitors
ProductCompanyStageHype Score
Olaratumab + Doxorubicin + Ifosfamide + MesnaEli LillyPhase 1
29
Anlotinib HydrochlorideSun PharmaceuticalPhase 2
31
Eribulin mesylate 1.4 mg/m^2 intravenous + Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IVEisaiPhase 3
40
Eribulin mesylateEisaiPre-clinical
26
E7389EisaiPhase 2
35
eribulin mesylateEisaiPhase 2
35
Olaratumab + Gemcitabine + Docetaxel + PlaceboEli LillyPhase 1/2
32
LY573636-sodiumEli LillyPhase 2
35
OlaratumabEli LillyPre-clinical
26
Olaratumab + Doxorubicin + PlaceboEli LillyPhase 3
40
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + DoxorubicinEli LillyPhase 1
29
Olaratumab + Pembrolizumab (KEYTRUDA®)Eli LillyPhase 1
29
Olaratumab + doxorubicinEli LillyPhase 1/2
32
TrabectedinJohnson & JohnsonPre-clinical
26
Doxorubicin + Trabectedin + DexamethasoneJohnson & JohnsonPhase 1
29
Camrelizumab in Combination With Neoadjuvant ChemotherapyJiangsu Hengrui MedicinePhase 2
31
Durvalumab and Tremelimumab + DoxorubicinAstraZenecaPhase 2
35
Standard arm: Trabectedin in monotherapy + Experimental arm: Trabectedin + OlaparibAstraZenecaPhase 2
35
trabectedin + olaparibAstraZenecaPhase 1
29